Limiting the extent of a delayed hemolytic transfusion reaction with automated red blood cell exchange

Archives of Pathology and Laboratory Medicine

Volumn 137, Issue 6, 2013, Pages 861-864

  Tormey, Christopher A ^a,b   Stack, Gary ^a,b  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; AUTOMATION; BLOOD GROUP INCOMPATIBILITY; CASE REPORT; ERYTHROCYTE TRANSFUSION; EXCHANGE BLOOD TRANSFUSION; HEMOLYSIS; HUMAN; IMMUNOLOGY; MALE; METHODOLOGY; TIME; TREATMENT OUTCOME;

AGED; AUTOMATION; BLOOD GROUP INCOMPATIBILITY; ERYTHROCYTE TRANSFUSION; EXCHANGE TRANSFUSION, WHOLE BLOOD; HEMOLYSIS; HUMANS; MALE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84879619052     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2012-0154-CR     Document Type: Article

References (20)

1. Davenport RD. Hemolytic transfusion reactions. In: Popovsky MA, ed. Transfusion Reactions. 3rd ed. Bethesda, MD: AABB Press; 2007:1-56.
2. Taylor C, Cohen H, Mold D, et al; on behalf of the Serious Hazards of Transfusion (SHOT) Steering Group. The 2009 Annual SHOT Report. Manchester, United Kingdom; 2010.
3. US Food and Drug Administration (FDA). Fatalities reported to FDA following blood collection and transfusion. http://www.fda.gov/ BiologicsBloodVaccines/ SafetyAvailability/ReportaProblem/ TransfusionDonationFatalities/ucm302847.htm. Accessed August 21, 2012.
4. Freiesleben E. Fatal hemolytic transfusion reaction due to anti-Fya. Acta Pathol Microbiol Scand. 1951;29(3):283-286.
5. Hillman NM. Fatal delayed hemolytic transfusion reaction due to anti-c E. Transfusion. 1979;19(5):548-551. (Pubitemid 10178348)
6. Schorn TF, Knospe WH. Fatal delayed hemolytic transfusion reaction without previous blood transfusion. Ann Intern Med. 1989;110(3):241-242. (Pubitemid 19041782)
7. Sancho JM, Pujol M, Fernández F, Soler M, Manzano P, Feliu E. Delayed haemolytic transfusion reaction due to anti-M antibody. Br J Haematol. 1998; 103(1):268-269. (Pubitemid 28470830)
8. Carson TH, ed. Standards for Blood Banks and Transfusion Services. 27th ed. Bethesda, MD: AABB Press; 2011.
9. Szczepiorkowski ZM, Winters JL, Bandarenko N, et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher. 2010;25(3):83-177.
10. von Zabern I, Ehlers M, Grunwald U, Mauermann K, Greinacher A. Release of mediators of systemic inflammatory response syndrome in the course of a severe delayed hemolytic transfusion reaction caused by anti-D. Transfusion. 1998;38(5):459-468. (Pubitemid 28287503)
11. Kalyanaraman M, Heidemann SM, Sarnaik AP, Meert KL, Sarnaik SA. Antis antibody-associated delayed hemolytic transfusion reaction in patients with sickle cell anemia. J Pediatr Hematol Oncol. 1999;21(1):70-73. (Pubitemid 29132000)
12. Tormey CA, Stack G. Estimation of combat-related blood group alloimmunization and delayed serologic transfusion reactions in U.S. military veterans. Mil Med. 2009;174(5):503-507.
13. McLeod BC, Sniecinski I, Ciavarella D, et al. Frequency of immediate adverse effects associated with therapeutic apheresis. Transfusion. 1999; 39(3): 282-288. (Pubitemid 29144913)
14. Knowles S, Cohen H; on behalf of the Serious Hazards of Transfusion (SHOT) Steering Group. The 2010 Annual SHOT Report. Manchester, United Kingdom; 2011.
15. Taylor C, Cohen H, Mold D, et al; on behalf of the Serious Hazards of Transfusion (SHOT) Steering Group. The 2008 Annual SHOT Report. Manchester, United Kingdom; 2009.
16. Taylor C, Cohen H, Stainsby D, et al; on behalf of the Serious Hazards of Transfusion (SHOT) Steering Group. The 2007 Annual SHOT Report. Manchester, United Kingdom; 2008.
17. Stainsby D, Jones H, Asher D, et al. Serious hazards of transfusion: a decade of hemovigilance in the UK. Transfus Med Rev. 2006;20(4):273-282. (Pubitemid 44428107)
18. Tormey CA, Stack G. The characterization and classification of concurrent blood group antibodies. Transfusion. 2009;49(12):2709-2718.
19. Tormey CA, Stack G. The persistence and evanescence of blood group alloantibodies in men. Transfusion. 2009;49(3):505-512.
20. Schwickerath V, Kowalski M, Menitove JE. Regional registry of patient alloantibodies: first-year experience. Transfusion. 2010;50(7):1465-1470.